<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00787267</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00008303</org_study_id>
    <nct_id>NCT00787267</nct_id>
  </id_info>
  <brief_title>Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC</brief_title>
  <acronym>TOP0801</acronym>
  <official_title>Phase II Study of Dasatinib in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      On this study patients will receive dasatinib, a targeted therapy, for advanced NSCLC that
      has progressed after previous therapy. Safety and response to dasatinib will be assessed.

      Fresh frozen tumor tissue must be available for genomics analysis prior to initiating
      dasatinib therapy. A biopsy must be obtained after any prior chemotherapy. If fresh frozen
      tumor tissue is not available, a biopsy will be required to participate in this trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lung cancer is the leading cause of cancer death in the United States. Twenty to seventy-five
      percent of patients initially treated with surgery or radiotherapy recur and become
      candidates for systemic therapy. Src expression has been identified in a majority of NSCLC
      cell lines and may be important in hypoxic growth and angiogenesis of NSCLC.

      This phase II trial will investigate the activity of the oral Src inhibitor dasatinib in
      advanced stage NSCLC. We hypothesize that the inhibition of Src pathway with dasatinib will
      show anti-tumor activity in advanced NSCLC, with a tolerable safety profile.

      Fresh frozen tissue is needed for the genomics analysis, thus a biopsy will be required to
      participate in this trial. The genomic analysis will determine if the tumor is Src-active or
      Src-inactive and responses to dasatinib compared. In stage I, 40 patients will be treated
      without prior knowledge of their tumoral Src-activity. If all stage I responses are observed
      in the Src-active patients, the second stage will only accrue that cohort. If all responses
      are observed in the Src-inactive cohort, the activity of dasatinib and genomic determination
      of dasatinib response will be re-evaluated. Otherwise, if during Stage I, responses are
      observed in both cohorts, they will be accrued separately and evaluated in a two-stage
      manner.

      Dasatinib will be give orally twice daily and continue until progression of disease,
      intolerable toxicity or patient withdrawal. Imaging studies will be done pre-treatment then
      every 6 weeks to assess radiologic response to therapy.

      Patients will be followed for 30 days after the last dose of dasatinib to assess toxicity.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor accrual
  </why_stopped>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor Response</measure>
    <time_frame>2 years</time_frame>
    <description>Tumor response rate was defined by RECIST criteria:
CR (complete response) = disappearance of all target lesions taking as reference the baseline sum of the longest diameter (LD); PR (partial response) = at least a 30% decrease in the sum of the longest diameter of target lesions; PD (progressive disease) = at least a 20% increase in the sum of the longest diameter of target lesions as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; SD (stable disease) = Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum LD since the treatment started</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Progression and survival every 6 months</time_frame>
    <description>Overall survival (OS) is the duration from date of consent to date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade 3-5 Toxicity Associated With Dasatinib Treatment</measure>
    <time_frame>Duration of dasatinib treatment plus 30 days</time_frame>
    <description>Number of subjects with Grade 3-5 toxicity as assessed using NCI CTCAE criteria with the attribution of possibly, probably, or definitely related to protocol treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe Change in Serum Levels of C-terminal Cross-linked Collagen I Between Pre-treatment and 6 Weeks After Starting Dasatinib.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine Relationship Between K-ras Gene Mutation and Response to Dasatinib.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Dasatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After a biopsy is done to obtain fresh frozen tumor tissue (Stage I), dasatinib is to be administered as an oral dose of 70 mg twice daily on a continuous basis for 6 weeks. Every 6 weeks radiologic exam will be done to assess response. Treatment will continue until progression of disease, intolerable toxicity or patient withdrawal.
For Stage II, a biopsy to obtain fresh frozen tumor tissue will also be done. Depending on results from Stage I and results of biopsy, treatment with dasatinib will be determined.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <description>70 mg PO twice daily until progression. Re-assess radiographically every 6 weeks.</description>
    <arm_group_label>Dasatinib</arm_group_label>
    <other_name>Sprycel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histological/cytological documented non-small cell lung cancer (NSCLC). Documentation
             of recurrence required if treated with surgical resection and/or external beam
             radiation therapy (XRT) with curative intent and now have recurrent disease.

          2. Fresh tissue biopsy material for genomics analysis prior to initiating dasatinib. If
             prior XRT, tissue biopsy must be outside XRT field. Biopsy must be after any prior
             chemotherapy.

          3. Prior treatment (tx) to include one of the following:

               -  At least 1 prior systemic regimen (IV or oral agent) for Stage IV NSCLC or for
                  recurrent disease.

               -  Recurrence within 12 months after completion of systemic neoadjuvant/adjuvant
                  chemotherapy for early stage NSCLC.

               -  Combined modality platinum-based tx for Stage III NSCLC.

          4. Prior XRT permitted if ≥1 week since completion, XRT must be &lt;25% of bone marrow
             reserve.

          5. At least one, non-radiated, measurable lesion (per RECIST).

          6. Age ≥18 years.

          7. Eastern Cooperative Oncology Group (ECOG) 0-2.

          8. Adequate Organ Function:

               1. Total bilirubin &lt; Upper limit normal (ULN)

               2. Hepatic enzymes (AST, ALT) ≤2.5x ULN

               3. Serum creatinine &lt;1.5x ULN

               4. Hemoglobin ≥9 gm/dL

               5. Neutrophil count (ANC/AGC) ≥1500 per μL

               6. Platelets ≥100,000 per μL

               7. Prothrombin time (PT)/a Partial thromboplastin time (PTT) ≤1.5x control

          9. No other serious medical or psychiatric illness.

         10. Ability to take oral medication (dasatinib must be swallowed whole).

         11. Women of childbearing potential must have negative serum pregnancy test ≤72 hours and
             not &gt;7 days prior to starting study drug.

         12. Sexually active males and females of reproductive potential must agree to use adequate
             method of contraception during tx and for at least 4 weeks after study drug stopped.

         13. Signed, written informed consent including Health Insurance Portability and
             Accountability Act (HIPAA) according to institutional guidelines.

        Exclusion Criteria:

          1. Previous or concomitant malignancy in past 2 years other than curatively treated
             carcinoma in situ of cervix, or basal cell/squamous cell carcinoma of the skin.

          2. Prior tx with dasatinib or other agents that inhibit Src.

          3. Evidence of symptomatic pleural effusions (grade 2) unless undergo therapeutic
             thoracentesis as part of non-study care. Successful pleurodesis allowed. Patients who
             require supplemental oxygen or with oxygen saturation on room air &lt;89% are not
             eligible. Pericardial effusions of any grade are not eligible.

          4. Untreated documented symptomatic central nervous system (CNS) metastases.

          5. Cardiac Symptoms:

               1. Uncontrolled angina, congestive heart failure(CHF)or myocardial infarction within
                  6 months

               2. Diagnosed congenital long QT syndrome

               3. Any h/o clinically significant ventricular arrhythmias

               4. Prolonged QT corrected (QTc) interval on pre-entry EKG (&gt;450 msec)

               5. Uncontrolled B/P as defined as &gt;160/90 on B/P therapy

          6. Hypokalemia or hypomagnesaemia if it cannot be corrected.

          7. H/o diagnosed congenital acquired bleeding disorders.

          8. Ongoing or recent (≤3 months) significant (≥grade 3) GI bleeding.

          9. Con Meds:

               1. Drugs having risk of causing Torsades de Pointes (must stop drug 7 days before
                  dasatinib);

               2. Current therapeutic dose unfractionated heparin, low-molecular weight heparin, or
                  coumadin therapy;

               3. St. John's Wort must be stopped while on dasatinib;

               4. IV bisphosphonates stopped 2 weeks pre/6 weeks post dasatinib.

         10. Prisoners/subjects compulsorily detained for tx of psychiatric and/or physical
             illness.

         11. Pregnant or breastfeeding.

         12. Active or uncontrolled infection requiring IV antibiotics.

         13. Impairment of GI function/disease that may alter absorption of dasatinib (e.g.,
             ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome,
             or small bowel resection).

         14. Received investigational drugs ≤4 weeks prior to starting study drug and/or not
             recovered from side effects of such therapy. Any other anti-neoplastic and/or
             molecular therapy must be discontinued 7 days prior to starting dasatinib.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Kelley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Durham VA Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Raleigh</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.genome.duke.edu/</url>
    <description>Duke Institute for Genome Sciences &amp; Policy</description>
  </link>
  <reference>
    <citation>Downward J. Cancer biology: signatures guide drug choice. Nature. 2006 Jan 19;439(7074):274-5.</citation>
    <PMID>16421553</PMID>
  </reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2008</study_first_submitted>
  <study_first_submitted_qc>November 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2008</study_first_posted>
  <results_first_submitted>December 19, 2014</results_first_submitted>
  <results_first_submitted_qc>December 19, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 1, 2015</results_first_posted>
  <last_update_submitted>May 31, 2016</last_update_submitted>
  <last_update_submitted_qc>May 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>Dasatinib</keyword>
  <keyword>Genomics</keyword>
  <keyword>Genomics analysis</keyword>
  <keyword>Genomic signature</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study opened to enrollment in November 2008 and closed in October 2011 due to slow accrual. Subjects were enrolled at 3 sites: Duke University Medical Center, Durham VA Medical Center, and the University of Minnesota. All subjects were enrolled in Stage 1, in which prior knowledge of each subject's tumoral Src-activity was not known.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Dasatinib</title>
          <description>Dasatinib: 70 mg PO twice daily until progression.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37">Signed a consent form</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25">Received at least one dose of study drug</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Screen failure/Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No Reason Provided</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All consented subjects included in baseline analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>Dasatinib</title>
          <description>Dasatinib: 70 mg PO twice daily until progression.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="37"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.7" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tumor Response</title>
        <description>Tumor response rate was defined by RECIST criteria:
CR (complete response) = disappearance of all target lesions taking as reference the baseline sum of the longest diameter (LD); PR (partial response) = at least a 30% decrease in the sum of the longest diameter of target lesions; PD (progressive disease) = at least a 20% increase in the sum of the longest diameter of target lesions as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; SD (stable disease) = Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum LD since the treatment started</description>
        <time_frame>2 years</time_frame>
        <population>Unable to determine the response for 9 subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib</title>
            <description>Dasatinib: 70 mg PO twice daily until progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Response</title>
          <description>Tumor response rate was defined by RECIST criteria:
CR (complete response) = disappearance of all target lesions taking as reference the baseline sum of the longest diameter (LD); PR (partial response) = at least a 30% decrease in the sum of the longest diameter of target lesions; PD (progressive disease) = at least a 20% increase in the sum of the longest diameter of target lesions as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; SD (stable disease) = Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum LD since the treatment started</description>
          <population>Unable to determine the response for 9 subjects.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progression of Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall survival (OS) is the duration from date of consent to date of death from any cause.</description>
        <time_frame>Progression and survival every 6 months</time_frame>
        <population>All subjects who received at least one dose of dasatinib were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib</title>
            <description>Dasatinib: 70 mg PO twice daily until progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival (OS) is the duration from date of consent to date of death from any cause.</description>
          <population>All subjects who received at least one dose of dasatinib were included in the analysis.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" lower_limit="2.3" upper_limit="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Grade 3-5 Toxicity Associated With Dasatinib Treatment</title>
        <description>Number of subjects with Grade 3-5 toxicity as assessed using NCI CTCAE criteria with the attribution of possibly, probably, or definitely related to protocol treatment.</description>
        <time_frame>Duration of dasatinib treatment plus 30 days</time_frame>
        <population>All subjects who received at least one dose of dasatinib were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib</title>
            <description>Dasatinib: 70 mg PO twice daily until progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Grade 3-5 Toxicity Associated With Dasatinib Treatment</title>
          <description>Number of subjects with Grade 3-5 toxicity as assessed using NCI CTCAE criteria with the attribution of possibly, probably, or definitely related to protocol treatment.</description>
          <population>All subjects who received at least one dose of dasatinib were included in the analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Describe Change in Serum Levels of C-terminal Cross-linked Collagen I Between Pre-treatment and 6 Weeks After Starting Dasatinib.</title>
        <time_frame>2 years</time_frame>
        <population>Assays were not run because no objective tumor response was observed.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib</title>
            <description>Dasatinib: 70 mg PO twice daily until progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Describe Change in Serum Levels of C-terminal Cross-linked Collagen I Between Pre-treatment and 6 Weeks After Starting Dasatinib.</title>
          <population>Assays were not run because no objective tumor response was observed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Determine Relationship Between K-ras Gene Mutation and Response to Dasatinib.</title>
        <time_frame>2 years</time_frame>
        <population>Assays were not run because no objective tumor response was observed.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib</title>
            <description>Dasatinib: 70 mg PO twice daily until progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Determine Relationship Between K-ras Gene Mutation and Response to Dasatinib.</title>
          <population>Assays were not run because no objective tumor response was observed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Evalulable Patients That Received Dasatinib</title>
          <description>Dasatinib: 70 mg PO twice daily until progression.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>decreased hemoglobin</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>decreased leukocytes</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>anorexia</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>dehydration</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>hyponatremia - metabolic/lab</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>muscle weakness (generalized)</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>neuro-motor (generalized weakness)</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>pericardial effusion</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnea</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>decreased hemoglobin</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>decreased neutrophils</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>elevated AST</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>neutrophils (neutropenia)</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>pulmonary edema</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>flatulence</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>taste alteration</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>anorexia</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>dizziness (lightheadedness)</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>edema (periorbital/face)</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>elevated LDH</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>leukocytosis</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>muscle weakness - lower extremity (leg weakness)</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>muscle weakness (generalized)</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>pain extremity (legs)</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>pedal edema</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>weight loss</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>myalgias (generalized)</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>pain-joint</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>elevated creatinine</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>renal/genitourinary other (slow starting urinary stream)</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>bronchospasm (wheezing)</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>dyspnea</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>hypoxia</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>pleural effusion</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>pleural effusion, bilateral</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>hair loss (alopecia)</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>rash</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>ulcers (scrotal)</sub_title>
                <description>NCI CTCAE version 3.0</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Kelley , MD</name_or_title>
      <organization>Duke University Medical Center</organization>
      <phone>919-286-0411 ext 7326</phone>
      <email>kelleym@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

